Key facts
- It has raised $12.8M across 1 recorded rounds; the latest was Seed Round ($671K) in Apr 2026.
- Notable investors include US National Science Foundation, Texas Medical Center, Matter (Consulting Services (B2B)), Builders VC, Wisconsin Economic Development — 16 tracked in total.
- NovaScan has filed 3 Form Ds with the SEC since 2021, most recently May 2026 ($671K sold to 4 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for NovaScan
Funding rounds
1 roundsAbout NovaScan
Developer of a non-invasive virus detection platform designed for cancer detection and stratification. The company has active programs in skin, lung, GI, and breast cancer, and its technology can be used in minimally invasive procedures and can be used to dose therapeutics into live tumors, enabling physicians to improve patient outcomes, increase physician economics, and reduce the cost of care.
- Sector
- Healthcare
- HQ
- Chicago, IL, United States
- Founded
- 2003
- Employees
- 16
- Website
- novascaninc.com/
- Ownership
- Privately Held (backing)
NovaScan doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NovaScan shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NovaScan in its N-PORT filings yet. We sweep new filings monthly.